What is Kazano, and what does its prescribing information cover?
Kazano is a brand name for a fixed-dose combination of alogliptin and metformin for treating type 2 diabetes. Its prescribing information typically includes the approved indications, important dosing instructions, warnings and precautions, adverse reactions, and information on contraindications and use in specific populations.
If you want, tell me whether you need the U.S. (FDA) label or another country’s version, and I can format the exact “Prescribing Information” sections accordingly.
How is Kazano usually dosed?
Kazano dosing depends on the patient’s diabetes control and how much metformin they were already taking (since Kazano contains fixed amounts). Prescribing information also explains how to start therapy and how to adjust for tolerability, including gastrointestinal side effects commonly associated with metformin.
What warnings and precautions appear in Kazano’s label?
Kazano’s prescribing information includes safety topics that commonly apply to DPP-4 inhibitors and metformin combinations, such as:
- Risks related to pancreatitis (as described in the label)
- Lactic acidosis risk associated with metformin, including situations that increase risk
- Hypoglycemia risk (generally lower when not used with insulin or a sulfonylurea, but addressed in label language)
- Renal impairment guidance, since metformin use depends on kidney function
What side effects are listed?
Kazano prescribing information includes adverse reactions seen in clinical use. Commonly, these include gastrointestinal symptoms tied to metformin (for example, nausea or diarrhea), along with other events described in the label.
Who should not take Kazano (contraindications)?
The label describes situations where Kazano should not be used. For metformin-containing products, this often includes conditions that raise the risk of lactic acidosis and certain severe kidney-related limitations. The exact wording and criteria are in the prescribing information.
What monitoring does Kazano require?
Kazano prescribing information typically calls for:
- Kidney function monitoring (baseline and periodic)
- Monitoring for symptoms that could indicate rare but serious risks described in warnings (such as lactic acidosis)
Can Kazano be used in kidney disease or in older adults?
The prescribing information provides specific thresholds and cautions related to kidney function and may include guidance for dose adjustment or discontinuation based on estimated glomerular filtration rate (eGFR). It also addresses special considerations for older adults, since metformin safety depends on renal function.
Drug interactions: what does the label warn about?
Prescribing information for metformin-based combinations commonly discusses interactions that can affect kidney function, metformin levels, or diabetes control. If you share your other medications (or if you’re looking for a specific interaction like with diuretics, contrast dye, or insulin), I can help you locate the relevant section in the Kazano label.
---
Quick clarification so I can provide the exact prescribing information
Which one do you want?
1) Kazano (alogliptin/metformin) U.S. FDA prescribing information, or
2) another country’s label?
Also, do you want the full label text or a section-by-section summary (Indications, Dosage & Administration, Contraindications, Warnings, Adverse Reactions, Drug Interactions, Use in Specific Populations)?